Your browser doesn't support javascript.
loading
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
Cederkrantz, Elin; Andersson, Håkan; Bernhardt, Peter; Bäck, Tom; Hultborn, Ragnar; Jacobsson, Lars; Jensen, Holger; Lindegren, Sture; Ljungberg, Michael; Magnander, Tobias; Palm, Stig; Albertsson, Per.
Afiliación
  • Cederkrantz E; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Andersson H; Department of Oncology, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Bernhardt P; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Bäck T; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Hultborn R; Department of Oncology, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Jacobsson L; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Jensen H; PET and Cyclotron Unit, Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
  • Lindegren S; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Ljungberg M; Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden.
  • Magnander T; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Palm S; Department of Radiation Physics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Albertsson P; Department of Oncology, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Electronic address: per.albertsson@oncology.gu.se.
Int J Radiat Oncol Biol Phys ; 93(3): 569-76, 2015 Nov 01.
Article en En | MEDLINE | ID: mdl-26460999
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Fragmentos Fab de Inmunoglobulinas / Astato / Radioinmunoterapia / Inmunoconjugados / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2015 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Fragmentos Fab de Inmunoglobulinas / Astato / Radioinmunoterapia / Inmunoconjugados / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2015 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos